Novavax Reports Q3 Loss of $0.19 a Share, Below FactSet Estimate

Novavax’s third-quarter revenue edged lower year over year, while its net loss narrowed as operating expenses fell sharply, including lower research and development and selling, general and administrative costs and no repeat of the prior-year impairment charge. Lower Sanofi licensing revenue partly…